Effect of rapamycin on aging and age-related diseases—past and future

[1]  D. Leaf,et al.  Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFNγ in NK cells. , 2020, The Journal of clinical investigation.

[2]  M. Blasco,et al.  The mTOR pathway is necessary for survival of mice with short telomeres , 2020, Nature Communications.

[3]  S. Austad,et al.  Bring Back the Rat! , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  B. Everts,et al.  Pathogens MenTORing Macrophages and Dendritic Cells: Manipulation of mTOR and Cellular Metabolism to Promote Immune Escape , 2020, Cells.

[5]  Xiaodong Han,et al.  Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation , 2019, Aging.

[6]  Gennifer E. Merrihew,et al.  Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment , 2019, Aging cell.

[7]  A. Lorenzini,et al.  Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial , 2019, GeroScience.

[8]  Guorong Wu,et al.  Melatonin and Rapamycin Attenuate Isoflurane-Induced Cognitive Impairment Through Inhibition of Neuroinflammation by Suppressing the mTOR Signaling in the Hippocampus of Aged Mice , 2019, Front. Aging Neurosci..

[9]  S. Austad,et al.  mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging , 2019, Aging cell.

[10]  M. Blagosklonny.  Rapamycin for longevity: opinion article , 2019, Aging.

[11]  Li-ping Chen,et al.  Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model , 2019, Neuroscience Letters.

[12]  Freddie H. Fu,et al.  Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem/Progenitor Cells from Progeroid Mice , 2019, Molecular therapy. Methods & clinical development.

[13]  T. Sargeant,et al.  Rapamycin and Alzheimer disease: a double-edged sword? , 2019, Autophagy.

[14]  Dudley Lamming,et al.  Next generation strategies for geroprotection via mTORC1 inhibition. , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  M. Kaeberlein,et al.  Rapamycin and Alzheimer’s disease: Time for a clinical trial? , 2019, Science Translational Medicine.

[16]  Eyal Amiel,et al.  Regulation of Dendritic Cell Immune Function and Metabolism by Cellular Nutrient Sensor Mammalian Target of Rapamycin (mTOR) , 2019, Front. Immunol..

[17]  Akira Yoshii,et al.  Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Tsc-1-Suppressed Brain , 2018, Front. Mol. Neurosci..

[18]  D. Butterfield,et al.  Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome , 2018, Translational Neurodegeneration.

[19]  C. Ross,et al.  Long‐term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle‐aged marmosets , 2018, American journal of primatology.

[20]  M. Beibel,et al.  TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.

[21]  J. Bielas,et al.  Long term rapamycin treatment improves mitochondrial DNA quality in aging mice , 2018, Experimental Gerontology.

[22]  Yizhen Chen,et al.  [Neuroprotective effect of rapamycin against Parkinson's disease in mice]. , 2018, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[23]  T. Curiel,et al.  A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects , 2018, Experimental Gerontology.

[24]  G. Fisone,et al.  Inhibition of mTORC1 Signaling Reverts Cognitive and Affective Deficits in a Mouse Model of Parkinson’s Disease , 2018, Front. Neurol..

[25]  Z. Ungvari,et al.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. , 2018, American journal of physiology. Heart and circulatory physiology.

[26]  D. Harrison,et al.  Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice , 2018, Annals of the New York Academy of Sciences.

[27]  M. Hadamitzky,et al.  Repeated Systemic Treatment with Rapamycin Affects Behavior and Amygdala Protein Expression in Rats , 2018, The international journal of neuropsychopharmacology.

[28]  P. Validire,et al.  mTOR pathway activation drives lung cell senescence and emphysema. , 2018, JCI insight.

[29]  Jie Chen,et al.  Effects of rapamycin on growth hormone receptor knockout mice , 2018, Proceedings of the National Academy of Sciences.

[30]  Dong Zhou,et al.  Rapamycin Protects Sepsis-Induced Cognitive Impairment in Mouse Hippocampus by Enhancing Autophagy , 2016, Cellular and Molecular Neurobiology.

[31]  W. Swindell.  Rapamycin in mice , 2017, Aging.

[32]  Owen S. Skinner,et al.  Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome , 2017, Human molecular genetics.

[33]  Russell G. Jones,et al.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells. , 2017, Immunity.

[34]  D. Promislow,et al.  A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs , 2017, GeroScience.

[35]  E. Ho,et al.  Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2‐independent mechanism , 2017, Aging cell.

[36]  Anshi Wu,et al.  Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through β-amyloid accumulation and tau phosphorylation. , 2016, Molecular medicine reports.

[37]  D. Seals,et al.  Dietary rapamycin supplementation reverses age‐related vascular dysfunction and oxidative stress, while modulating nutrient‐sensing, cell cycle, and senescence pathways , 2016, Aging cell.

[38]  Wei Zhang,et al.  Neuroprotective Effects of Salidroside in the MPTP Mouse Model of Parkinson's Disease: Involvement of the PI3K/Akt/GSK3β Pathway , 2016, Parkinson's disease.

[39]  Jinhui Chen,et al.  Traumatic Brain Injury Stimulates Neural Stem Cell Proliferation via Mammalian Target of Rapamycin Signaling Pathway Activation , 2016, eNeuro.

[40]  Kathleen F. Kerr,et al.  Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice , 2016, eLife.

[41]  Bethany Halford,et al.  Rapamycin’s secrets unearthed , 2016 .

[42]  D. Féliers,et al.  Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes. , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[43]  S. A. Arriola Apelo,et al.  Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[44]  Dudley Lamming,et al.  Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer , 2016, Aging cell.

[45]  P. Cortelli,et al.  Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording , 2016, Parkinson's disease.

[46]  Wei Zhang,et al.  Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  R. Siman,et al.  The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy , 2015, PloS one.

[48]  S. Tardif,et al.  Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus) , 2015, Aging.

[49]  T. Weichhart,et al.  Regulation of innate immune cell function by mTOR , 2015, Nature Reviews Immunology.

[50]  Randy Strong,et al.  NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model , 2015, EBioMedicine.

[51]  T. Curiel,et al.  Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice , 2015, Aging cell.

[52]  L. Zender,et al.  mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype , 2015, Nature Cell Biology.

[53]  A. Richardson,et al.  How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story , 2015, Experimental Gerontology.

[54]  P. Rabinovitch,et al.  Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice , 2015, Front. Genet..

[55]  P. Nelson,et al.  MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation , 2015, Nature Cell Biology.

[56]  C. Livi,et al.  p53 and rapamycin are additive , 2015, Oncotarget.

[57]  S. Krähenbühl,et al.  Acute Sirolimus Overdose: A Multicenter Case Series , 2015, PloS one.

[58]  A. Bokov,et al.  Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy , 2015, Pathobiology of aging & age related diseases.

[59]  J. Praestgaard,et al.  mTOR inhibition improves immune function in the elderly , 2014, Science Translational Medicine.

[60]  L. Tan,et al.  Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[61]  K. Limesand,et al.  Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms , 2014, Aging cell.

[62]  M. Hadamitzky,et al.  Acute systemic rapamycin induces neurobehavioral alterations in rats , 2014, Behavioural Brain Research.

[63]  M. Smithey,et al.  Immune Memory–Boosting Dose of Rapamycin Impairs Macrophage Vesicle Acidification and Curtails Glycolysis in Effector CD8 Cells, Impairing Defense against Acute Infections , 2014, The Journal of Immunology.

[64]  F. Neff,et al.  Longevity, aging and rapamycin , 2014, Cellular and Molecular Life Sciences.

[65]  B. Kaplan,et al.  Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.

[66]  X. Chen,et al.  Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis via Inhibiting NF-κB Activation , 2014, Mediators of inflammation.

[67]  M. MacCoss,et al.  Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart , 2014, Aging cell.

[68]  V. Anisimov,et al.  Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin , 2014, Cancer biology & therapy.

[69]  Z. D. Sharp,et al.  Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.

[70]  S. Austad,et al.  Rapamycin extends life and health in C57BL/6 mice. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[71]  W. Wood,et al.  Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major Changes in the Liver Transcriptome , 2014, PloS one.

[72]  M. Antoch,et al.  BMAL1-dependent regulation of the mTOR signaling pathway delays aging , 2014, Aging.

[73]  H. Remmen,et al.  Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts , 2013, Aging cell.

[74]  C. Livi,et al.  eRapa Restores a Normal Life Span in a FAP Mouse Model , 2013, Cancer Prevention Research.

[75]  R. Day,et al.  Inhibition of IGF-1R Prevents Ionizing Radiation-Induced Primary Endothelial Cell Senescence , 2013, PloS one.

[76]  Maureen A. McGargill,et al.  mTOR modulates the antibody response to provide cross-protective immunity to lethal influenza infections , 2013, Nature Immunology.

[77]  B. Kennedy,et al.  Late‐life rapamycin treatment reverses age‐related heart dysfunction , 2013, Aging cell.

[78]  H. Fuchs,et al.  Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.

[79]  P. Fox,et al.  Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[80]  L. Kappos,et al.  Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice , 2013, PloS one.

[81]  Pasko Rakic,et al.  A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss , 2013, The Journal of Neuroscience.

[82]  L. Leocani,et al.  Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of Tuberous Sclerosis Complex , 2013, Neuropharmacology.

[83]  A. Anderson,et al.  Rapamycin Reverses Status Epilepticus-Induced Memory Deficits and Dendritic Damage , 2013, PloS one.

[84]  J. Campisi,et al.  Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.

[85]  Alcino J. Silva,et al.  mTOR Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons , 2013, Neuron.

[86]  C. Soto,et al.  Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease , 2013, Nature Communications.

[87]  Ariel Orellana,et al.  Correction: Corrigendum: ER-localized auxin transporter PIN8 regulates auxin homoeostasis and male gametophyte development in Arabidopsis , 2013, Nature Communications.

[88]  C. Livi,et al.  Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors , 2013, Aging.

[89]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[90]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[91]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[92]  S. Austad,et al.  Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence , 2012, Experimental Gerontology.

[93]  S. Austad,et al.  Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice , 2012, Neuroscience.

[94]  M. Antoch,et al.  Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice , 2012, Aging.

[95]  M. Antoch,et al.  New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis , 2012, Aging.

[96]  F. Gruijl,et al.  Rapamycin impairs UV induction of mutant‐p53 overexpressing cell clusters without affecting tumor onset , 2012, International journal of cancer.

[97]  James B. Mitchell,et al.  mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. , 2012, Cell stem cell.

[98]  Michael G. Garelick,et al.  Rapamycin Reverses Elevated mTORC1 Signaling in Lamin A/C–Deficient Mice, Rescues Cardiac and Skeletal Muscle Function, and Extends Survival , 2012, Science Translational Medicine.

[99]  Jacqueline N. Crawley,et al.  Autistic-like behavior and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice , 2012, Nature.

[100]  T. V. Bykova,et al.  Suppression of replicative senescence by rapamycin in rodent embryonic cells , 2012, Cell cycle.

[101]  Xueyuan Bai,et al.  SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence , 2012, Mechanisms of Ageing and Development.

[102]  M. Bouchard,et al.  Inhibition of Mammalian Target of Rapamycin Augments Lipopolysaccharide-Induced Lung Injury and Apoptosis , 2012, The Journal of Immunology.

[103]  A. Caccamo,et al.  Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling , 2012, Aging cell.

[104]  K. Seung,et al.  Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic Total Occlusion Study (CATOS) trial. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[105]  S. Hursting,et al.  Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. , 2012, Endocrine-related cancer.

[106]  S. Komarova,et al.  Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. , 2012, Cancer letters.

[107]  Richie Soong,et al.  Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells , 2012, Cancer biology & therapy.

[108]  A. Gudkov,et al.  Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin , 2011, PloS one.

[109]  Smita Majumder,et al.  Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits , 2011, Alzheimer's & Dementia.

[110]  S. Toyooka,et al.  Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non‐small‐cell lung cancer cells , 2011, Cancer science.

[111]  Francis S Collins,et al.  Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Syndrome Cells , 2011, Science Translational Medicine.

[112]  M. Mita,et al.  Are we ready to move away from nature? The rapamycin story , 2011, Targeted Oncology.

[113]  S. Fischer,et al.  Rapamycin Partially Mimics the Anticancer Effects of Calorie Restriction in a Murine Model of Pancreatic Cancer , 2011, Cancer Prevention Research.

[114]  B. Ghanim,et al.  Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[115]  M. Mita,et al.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas , 2011, Targeted Oncology.

[116]  A. Brenner,et al.  Common toxicities of mammalian target of rapamycin inhibitors , 2011, Targeted Oncology.

[117]  T. Clackson,et al.  Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens , 2011, Molecular Cancer Therapeutics.

[118]  Liang Li,et al.  Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis , 2011, Autophagy.

[119]  B. Neel,et al.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. , 2011, The Journal of clinical investigation.

[120]  S. Kozma,et al.  Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage , 2011, Proceedings of the National Academy of Sciences.

[121]  R. de Cabo,et al.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[122]  H. Pitot,et al.  Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models , 2010, Cancer Prevention Research.

[123]  A. Kirk,et al.  Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses , 2010, The Journal of Immunology.

[124]  S. Oddo.  Molecular interplay between mTOR, Aβ and tau: Effects on cognitive impairments , 2010, Alzheimer's & Dementia.

[125]  J. Viña,et al.  Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[126]  C. Ching,et al.  Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. , 2010, The American journal of pathology.

[127]  M. Antoch,et al.  Rapamycin extends maximal lifespan in cancer-prone mice. , 2010, The American journal of pathology.

[128]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[129]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[130]  G. Koehl,et al.  Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APCMin/+ mice , 2010, Oncogene.

[131]  Lloyd A Greene,et al.  Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.

[132]  H. Katus,et al.  Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. , 2009, Journal of the American College of Cardiology.

[133]  R. Abraham,et al.  Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.

[134]  Yang Liu,et al.  mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells , 2009, Science Signaling.

[135]  Youming Peng,et al.  Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging , 2009, Mechanisms of Ageing and Development.

[136]  L. Chodosh,et al.  mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. , 2009, Cell stem cell.

[137]  R. Maldonado,et al.  Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling , 2009, Nature Neuroscience.

[138]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[139]  B. Winblad,et al.  Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer’s disease , 2009, Journal of cellular and molecular medicine.

[140]  M. Blagosklonny,et al.  Rapamycin decelerates cellular senescence , 2009, Cell cycle.

[141]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[142]  A. Sabichi,et al.  Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells , 2009, Clinical Cancer Research.

[143]  R. Hunter,et al.  Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells , 2009, Nature Medicine.

[144]  D. Dobrota,et al.  Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies , 2009, Journal of neurochemistry.

[145]  D. Praticò,et al.  Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor , 2009, British journal of pharmacology.

[146]  E. Abraham,et al.  Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. , 2009, American journal of respiratory cell and molecular biology.

[147]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[148]  K. Stuhlmeier,et al.  The TSC-mTOR signaling pathway regulates the innate inflammatory response. , 2008, Immunity.

[149]  H. Lane,et al.  Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ716 mice , 2008, Proceedings of the National Academy of Sciences.

[150]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[151]  A. Goldfarb-Rumyantzev,et al.  Diabetes after transplantation and sirolimus: what's the connection? , 2008, Journal of the American Society of Nephrology : JASN.

[152]  T. Münzel,et al.  Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. , 2008, Journal of the American College of Cardiology.

[153]  D. Teupser,et al.  Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.

[154]  A. Tolkovsky,et al.  Rapamycin Inhibits Polyglutamine Aggregation Independently of Autophagy by Reducing Protein Synthesis , 2008, Molecular Pharmacology.

[155]  E. Cohen.  mTOR: the mammalian target of replication. , 2008, Journal of Clinical Oncology.

[156]  P. Pandolfi,et al.  The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.

[157]  A. Abizaid.  Sirolimus-eluting coronary stents: a review , 2007, Vascular health and risk management.

[158]  K. Maekawa,et al.  Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[159]  T. Akasaka,et al.  Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. , 2006, Atherosclerosis.

[160]  A. Dart,et al.  Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis , 2006, Journal of hypertension.

[161]  D. Rubinsztein,et al.  Rapamycin alleviates toxicity of different aggregate-prone proteins. , 2006, Human molecular genetics.

[162]  Matt Kaeberlein,et al.  Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.

[163]  Matt Kaeberlein,et al.  Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients , 2005, Science.

[164]  David L. Williams,et al.  Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. , 2005, Cardiovascular research.

[165]  R. Pakala,et al.  Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice: Inhibitory Effect on Monocyte Chemotaxis , 2005, Journal of cardiovascular pharmacology.

[166]  J. Shay,et al.  Senescence and immortalization: role of telomeres and telomerase. , 2005, Carcinogenesis.

[167]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[168]  M. Boluyt,et al.  The mTOR/p70S6K Signal Transduction Pathway Plays a Role in Cardiac Hypertrophy and Influences Expression of Myosin Heavy Chain Genes in vivo , 2004, Cardiovascular Drugs and Therapy.

[169]  S. Izumo,et al.  Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.

[170]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[171]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[172]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[173]  Tibor Vellai,et al.  Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.

[174]  K. Mansfield,et al.  Marmoset models commonly used in biomedical research. , 2003, Comparative medicine.

[175]  W. Manning,et al.  Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.

[176]  C. Ballantyne,et al.  Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200 , 2002, Journal of Lipid Research.

[177]  C. Groth,et al.  Pharmacokinetics and Safety of Single Oral Doses of Sirolimus (Rapamycin) in Healthy Male Volunteers , 2000, Therapeutic drug monitoring.

[178]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[179]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[180]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[181]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[182]  L. Hayflick,et al.  The serial cultivation of human diploid cell strains. , 1961, Experimental cell research.

[183]  M. Javors,et al.  mTOR drives cerebral blood flow and memory deficits in LDLR−/− mice modeling atherosclerosis and vascular cognitive impairment , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[184]  C. Geula,et al.  Amyloid-β deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition , 2014, Acta Neuropathologica.

[185]  B. Hemmings,et al.  S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. , 2012, The Biochemical journal.

[186]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.